Phase 2 Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women between 18 and 75 years old at the time of signing the consent form.
- People with breast cancer that has spread, come back, or cannot be removed by surgery, where the cancer is confirmed by tissue testing to be ER-positive and HER2-negative.
- People who have previously received at least one hormone-based treatment (lasting 6 months or more) and no more than two rounds of chemotherapy for the advanced or returned stage of their disease (the chemotherapy limit applies to the dose-finding stage of the trial only); or, in the third stage of the trial, people who have not yet received treatment for advanced disease but whose cancer may be suitable for a CDK4/6 inhibitor type of therapy (confirm with trial site).
- People whose cancer has been confirmed by imaging scans to have grown or spread either during or after the last cancer treatment they received before joining the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a known or suspected allergy to any ingredient in HP568, or to any ingredient in palbociclib (the palbociclib allergy criterion applies to the third stage of the trial only).
- People who received the drug fulvestrant within 42 days before the first dose, or who received other hormone therapies such as tamoxifen, toremifene, letrozole, anastrozole, or exemestane within 14 days before the first dose.
- People who have previously received other drugs of a similar type to HP568, such as ARV-471 (confirm with trial site for full list).
- People who received nitrosourea or mitomycin chemotherapy drugs within 6 weeks before the first dose, or who received any other anti-cancer treatment — including immunotherapy, chemotherapy, radiation, or targeted therapy — within 28 days before the first dose (or within 5 half-lives of that treatment, whichever is shorter).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86-28-85058465
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Stage I: the incidence of TEAE of HP568; Stage I: Incidence of dose limiting toxicity DLT, maximum tolerated dose MTD (if possible).; Stage III: Evaluate safety during the dose escalation phase of combination therapy; Stage III: Evaluate tolerance during the dose escalation phase of combination therapy; Stage III: Evaluate the 24 week clinical benefit rate (CBR) during the dose escalation phase of combination therapy; Stage II: 24 week clinical benefit rate (CBR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.